Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1718-1722

  Duong, Vu H ^a,b   Bhatnagar, Bhavana ^a,b   Zandberg, Dan P ^a,b   Vannorsdall, Emily J ^a,b   Tidwell, Michael L ^a   Chen, Qing ^a,b   Baer, Maria R ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Azacitidine; Decitabine; Myelodysplastic syndromes

Indexed keywords

AZACITIDINE; DECITABINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE COURSE; DRUG TREATMENT FAILURE; ELECTRONIC MEDICAL RECORD; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATIENT PARTICIPATION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE;

EID: 84932097658     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.966708     Document Type: Article

References (32)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:A randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
2. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
3. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
4. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or highrisk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987-1996.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
6. Cashen AF, Schiller GJ, O' Donnell MRD, et al. Multicenter, phase II study of decitabine for thefirst-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
7. Kantarjian HM, Th omas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
8. Th epot S, Itzykson R, Seegers V, et al. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. Am J Hematol 2014; 89: 410-416.
9. Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma 2014; 55: 1533-1537.
10. Dombret H, Seymour JF, Butrym A, et al. Results of a phase 3, multicenter, randomized, open-label study of azacitidine (AZA) vs conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (AML). Haematologica 2014; 99(Suppl. 1): Abstract LB6212.
11. Steensma D P, Baer M R, Slack J L, et al. M ulticenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842-3848.
12. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma 2013; 54: 2003-2007.
13. Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol 2014; 93: 47-55.
14. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473-7478.
15. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine asfirst-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012; 97: 393-401.
16. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322-3327.
17. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116: 3830-3834.
18. Duong VH, Lin K, Reljic T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk 2013; 13: 711-715.
19. Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324-1341.
20. Hollenbach P W, Nguyen A N, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5: e9001.
21. Qin T, Jelinek J, Si J, et al. M echanisms of resistance to 5- Aza-2'-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659-667.
22. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008; 49: 690-695.
23. Braun T, Cherait A, Berthon C, et al. T reatment with decitabine (DAC) after azacitidine (AZA) failure in high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML). Blood 2013; 122(Suppl. 1): Abstract 2796.
24. Komrokji R S, A puri S, A l Ali N, et al. E vidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS). J Clin Oncol 2013; 31(Suppl.): Abstract 7113.
25. Greenberg P L, Tuechler H, Schanz J, et al. R evised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
26. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
27. Cheson B D, Greenberg P L, Bennett J M, et al. C linical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
28. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-1072.
29. Silverman L R. F urther analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
30. Silverman L R, Fenaux P, Mufti G J, et al. C ontinued azacitidine therapy beyond time offirst response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117: 2697-2702.
31. Kantarjian HM, Roboz GJ, Rizzieri DA, et al. Results from the dose escalation phase of a randomized phase 1-2first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SQ) second generation hypomethylating agent (HMA) in patients with relapsed/ refractory MDS and AML. Blood 2012; 120(Suppl. 1): Abstract 414.
32. O' Connell C, Tibes R, Walsh K, et al. Outcomes of intermediate or high risk myelodysplastic syndromes (MDS) patients post azacitidine and/or decitabine treatment failures with SGI-110, a novel second generation hypomethylating agent (HMA). Haematologica 2013; 98: 81-82.